Initial Estimates of the Minimal Clinically Important Difference (MCID) for the Neuropathic Pain Symptom Inventory (NPSI): A Systematic Meta-Analysis

Authors: Alexandra Canori, PhD[1], Rebecca Howard, MD[1], Jeffrey Bower, PhD[2], David Putrino, PhD[1], and Laura Tabacof, MD[1]

[1] Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, NY

[2] Sana Health Inc.

RUNNING TITLE: MCID FOR THE NPSI

Corresponding Author: Dr. Jeffrey Bower

- Email: jeff@sana.io
- Phone: 951-236-3007
- Institution URL: https://www.sana.io/
- Address:

  Sana Health, Inc. Attn: Jeffrey Bower

  2051 Dogwood St Ste. 220

  Louisville, CO 80027

Abstract:

Objective:

The Neuropathic Pain Symptom Inventory (NPSI) is commonly used assessment in Neuropathic Pain (NP) trials, yet a Minimal Clinically Important Difference (MCID) has not been established. A MCID would enhance the interpretability of NPSI scores, guiding clinicians and researchers in assessing clinically important improvements in NP symptoms. The aim of this study was to calculate an MCID from the available scientific research that used the NPSI.

Methods:

We conducted a systematic review and meta-analysis of NP trials reporting the NPSI. Three distributional approaches were applied to estimate the MCID: pooled standard deviation (SD) of change scores, pooled baseline SD, and a random-effects meta-analytic approach. Only treatments arms within RTCs were examined. Treatment arms were grouped by NP etiology, enabling etiology-specific MCID estimates. Bias for each included study was assessed using the Cochrane tool for quality assessment of randomized controlled trials.

Results:

323 trials were examined, 12 were selected for inclusion for a total of 17 treatment arms. The calculated MCID estimates for the NPSI total score were 7.95 using pooled SD of change scores, 7.73 using pooled baseline SD, and 6.85 using the random-effects method. Etiology-specific MCIDs varied, with Post-Infectious conditions and Diabetic Peripheral Neuropathy showing higher values than other NP types.

Conclusion:

This study provides preliminary MCID estimates for the NPSI. Limitations include limited data for certain NP subtypes, highlighting the need for additional anchor-based and etiology-specific MCID research to refine these estimates. These findings can aid in future NP trial design and the interpretation of results.

Key Words:

Neuropathic Pain, Neuropathic Pain Symptom Inventory, NPSI, Minimal Clinically Important Difference, MCID

Introduction:

Clinical trials have historically focused on establishing statistical significance as the main measure of clinical success. However, statistical significance does not indicate if the amount of improvement was large enough to be considered clinically meaningful. It is imperative for researchers and clinicians to communicate the clinical importance of their findings to accurately assess its utility to patients. This is especially important when evaluating conditions like neuropathic pain (NP), a multifaceted and chronic disorder that is diverse in causes and etiology, often causing considerable suffering and distress in patients.

Neuropathic pain is defined by the International Association for the Study of Pain as pain caused by a lesion or disease of the somatosensory nervous system resulting from complex pathophysiological mechanisms involving both peripheral and central nervous system dysfunctions [1]. NP affects roughly 10% of the general population and causes a decrease in quality of life and high healthcare costs, with the economic burden of neuropathic pain estimated to be significant due to both direct medical expenses and loss of productivity [2,3,4]. NP can either be spontaneous or evoked by stimuli, and presents with negative (e.g. numbness), or positive (e.g. parasthesia) symptoms [5]. To definitively diagnose NP, there must be evidence of damage to the nervous system, through radiological, neurophysiological, or tissue testing, accompanying a neuroanatomically accurate pain pattern. Chronic NP is defined as pain lasting at least 3 months and can be divided into peripheral or central etiologies [6]. Peripheral etiologies include diabetic neuropathy, postherpetic neuralgia, and radiculopathy [3]. Central etiologies include brain injury or spinal cord injury mediated, and post-stroke pain.

NP treatments span a wide range and includes anticonvulsive, antidepressant, or opiate analgesic medications as well as topical medications, surgical procedures, and neuromodulation. Evaluating the effectiveness of a diverse set of new and existing interventions is important to inform clinicians on effective treatment options [7]. NP can be assessed using standardized questionnaires, clinical examinations, and patient-reported symptoms. Reported symptoms such as burning, tingling, numbness, spontaneous pain, and sensory abnormalities support the diagnosis. Questionnaires can be categorized as screening questionnaires (for identifying patients with NP and distinguishing from non-neuropathic pain) and assessment questionnaires (for measuring symptoms and treatment response) [8].

The Neuropathic Pain Symptom Inventory (NPSI) is an assessment questionnaire that has gained popularity in NP trials due to its capacity to characterize neuropathic symptoms and to monitor treatment effectiveness [8,9]. The survey was developed in 2004 and assesses both the quantitative and qualitative properties of NP as a patient-reported outcome (PRO) [10]. It has been validated in more than 10 different languages for patients with both peripheral and central neuropathic pain [9]. It includes 12 items (10 descriptors of symptoms and 2 items for duration of spontaneous or paroxysmal pain) that categorize pain into 5 subscales of NP: burning pain, evoked pain, pressing pain, paroxysmal pain, and paresthesia/dysesthesia. These subscales can be examined individually or a total score can be computed that assesses overall NP severity. The NPSI total is calculated by summing the 10 descriptor items for a total score of 0-100, with higher scores indicating greater severity. The NPSI is a relatively new scale that is being used more frequently in trials of NP due to is excellent psychometric properties as well as its ability to

assess sub-domains of NP with its subscales. PROs like the NPSI align with the FDA's 2022 guidance on integrating patients' perspectives and using them as valid scientific evidence for assessing clinically relevant symptoms and improvement resulting from an intervention [11].

The Minimal Clinical Important Difference (MCID) is defined as the smallest difference in the instrument score that patients consider meaningful or beneficial [12]. It is particularly useful when evaluating PROs and maintains a patient-centered approach to evaluating clinical trials, allowing for identification of 'responders' to an intervention [13]. The MCID is a value used to assess the clinical relevance of a result that is not captured in the statistical comparison of means [12]. While statistical tests assess whether a difference exists, they do not necessarily indicate whether that difference was meaningful to patients. Statistical significance is heavily influenced by sample size, where a larger sample can make even small differences statistically significant [14]. In clinical trials, it is not uncommon to observe statistically significant results that are not of a magnitude that indicates a clinical improvement [13]. An MCID provides a criterion researchers can use to evaluate observed improvements from an intervention and provide a clearer picture of clinical importance.

In the absence of an a-priori MCID value from an external source, the FDA recommends the calculation of the MCID using the anchor method [15]. The anchor method is preferred as its estimate of MCID is determined by relating change on the PRO to an established measure of global improvement. Distributionally based MCIDs are only used in preference to anchor based when the latter is not available [16]. Distributionally based MCIDs have the disadvantages of being disconnected from any other measure of improvement and they tend to align with more

with statistical significance, such that a trial with a statistically significant result will often calculate a MCID that is less than their reported change, which does not add much information about clinical importance. This can be remedied somewhat by using MCID estimates that are external to the trial being conducted and are either from earlier pilot trials or from published research. An advantage of distributional methods is that they can often be calculated from reported statistics in published manuscripts, while calculating an MCID based on the anchor method, subject-by-subject data is necessary, and thus, cannot be calculated based on published results data. To estimate an MCID for the NPSI total based on published trials, using a distributional method will be necessary.

There are several distributional methods however most of them involve quantifying the variance of change scores from pre-post intervention. Some of the most common are using the Standard Error of the Mean as the MCID or by multiplying the SD of Change by a value chosen from a range of 0.25 to 0.5. The most common approach is to take ½ of a standard deviation of the change score of a treatment group within a trial [13]. It has been found that ½ a standard deviation corresponds to MCIDs calculated within a variety of trials, is highly correlated to using SEM as the MCID, and may represent the limits of human discrimination ability [17]. For this meta-analysis, we have determined that ½ a standard deviation is an appropriate value to use.

As of November 2024, no established MCID exists for the NPSI Total Score. The aim of this meta-analysis was to calculate an MCID from the available scientific research that used the NPSI to measure treatment response. Understanding the amount of change needed in the NSPI score for a clinically important improvement in NP symptoms will help clinicians and scientists to

evaluate the effectiveness of previously published interventions and inform future trial design for new NP treatments.

Materials and Methods:

Literature Search:

PubMed and Google Scholar databases were systematically searched for all relevant studies until October 2024. A literature search was performed using the following search terms: ("Neuropathic Pain Symptom Inventory"[Title/Abstract] OR "NPSI"[Title/Abstract]) AND ("randomized controlled trial"[Publication Type] OR "clinical trial"[Publication Type]). No restriction on publication dates was applied. A preliminary screening of titles and abstracts was followed by a review of full-text articles, which informed subsequent study selection.

Selection Criteria:

Clinical trials and randomized controlled trials that evaluated changes in pain using the NPSI in adults over the age of 18 were included. Case reports, abstracts, reviews, editorials, and publications that were unavailable in English were excluded during screening. During full-text review, studies were excluded for containing duplicate data, insufficient data to calculate overall NPSI score or change in NPSI score, or missing statistical values. One included study used the validated Thai version of the NPSI, all other included studies used the English version. The exclusion process is outlined by the PRISMA flowchart in Figure 1.

Figure 1: PRISMA flowchart

Data Extraction and Quality Assessment:

Two investigators extracted title, author, publication date, study design, patient population, sample size, mean age, sex, intervention, follow-up period, and NPSI scores. Methodological quality and confidence of each trial was assessed by reviewing methods of randomization, allocation concealment, blinding, selective reporting, and other biases in accordance with the Cochrane Risk of Bias (RoB) 2 tool for quality assessment of randomized controlled trials [18]. No review protocol is was created and the review was not registered.

Study Selection for Analyses:

Out of 323 papers in the initial search, 20 were examined to determine if they reported the required summary statistics or if they were derivable from other reported values. Studies were required to have reported either the SD of change or Baseline SD for the NPSI Total to be included in one of the analyses. In addition, each study was checked to ensure that the NPSI was calculated by convention (sum of 10 items). Within selected trials, only treatment arms were included in the analyses and data from placebo, waitlist, or inactive sham were excluded. After assessing the 20 articles, 12 were included in the final set for analysis with 17 treatment arms for the analysis (Table 1).

Table 1: Treatment Arms included in analyses. SMD is the Standardized Mean Difference.

Article	Paired Analyses	Baseline Analysis	Imputation Note	Patient Population	Analysis Category	Study Design	Intervention	Treatment Duration	N	Baseline Sd	Mean Change	SD of Change	SMD
Rocha, et al, 2014[19]	Exclude	Include	~	Upper limb CRPS1	CRPS	RCT	Thoracic Sympathetic Block	12 months	17	7.83	1.9	~	~

Rocha et al., 2014[19]	Exclude	Include	Baseline SD converted from SEM and N	Upper limb CRPS1	CRPS	RCT	Stellate Ganglion Block	12 months	19	12.20	1	~	~
Hoerder et al., 2023[20]	Exclude	Include	~	DPN	DPN	RCT	Acupuncture	14 weeks	31	15.80	10.7	~	~
Todorovic et al., 2022[21]	Exclude	Include	~	DPN	DPN	Crossover RCT	Lidocaine Intravenous	60 minutes	17	19.50	~	~	~
Schlaeger, et al., 2017[22]	Exclude	Include	~	Sickle cell disease pain	Other Disease	RCT	Pregabalin	3 months	11	13.00	8.1	~	~
Culver et al., 2017[23]	Include	Include	~	Sarcoid-associated with small nerve fiber loss	Other Disease	RCT	Cibinetide 1mg	28 days	15	20.00	14.5	17.9	0.81
Culver et al., 2017[23]	Include	Include	~	Sarcoid-associated with small nerve fiber loss	Other Disease	RCT	Cibinetide 4mg	28 days	15	20.80	8.4	12.7	0.66
Culver et al., 2017[23]	Include	Include	~	Sarcoid-associated with small nerve fiber loss	Other Disease	RCT	Cibinetide 8mg	28 days	16	17.10	12.9	13.8	0.93
Rehm, Binder, & Baron, 2010[24]	Include	Include	Multiplied NPSI Total scores by 10 to match convention	Postherpetic neuralgia	Post Infectious	RCT	Lidocaine	4 weeks	50	15.80	16	17.3	0.92
Rehm, Binder, & Baron, 2010[24]	Include	Include	Multiplied NPSI Total scores by 10 to match convention	Postherpetic neuralgia	Post Infectious	RCT	Pregabalin	4 weeks	48	15.80	14	18.7	0.75
Raksakietisak et al., 2022[25]	Exclude	Include	Used Wan et al., (2014) method to convert medians and quartiles to baseline mean and SD[26]	Post-cervical spine surgery pain	Surgical	RCT	Nefopam	30 days	25	6.30	~	~	~

Juhl, Karlsso, & Damsgaard 2016[27]	Include	Include	Change SD estimated from p-value of change, N, and mean change. Active p < 0.001 or estimated at p = 0.00099.	Post-mastectomy pain	Surgical	RCT	Fat Grafting	6 months	8	10.00	13.7	7.15	1.92
Martinez, et al, 2013[28]	Include	include	~	Post-discectomy radicular pain	Surgical	RCT	Minocycline	3 months	51	17.00	17	18	0.94
Ushida, et al., 2023[29]	Include	Exclude	~	SCI	Central Nervous System	RCT	Mirogabalin	14 weeks	150	~	12.0	15.47	~
Kim, et al., 2020[30]	Include	Include	~	Central neuropathic pain	Central Nervous System	RCT	Intermittent Theta Burst TMS	5 days	15	15.86	13	9.15	1.42
Wong, Widerstrom-Nog, & Field-Fote, 2022[31]	Include	Include	~	SCI	Central Nervous System	RCT	8-Dose Wholebody Vibration	2 weeks	8	15.00	10	5	2.00
Wong, Widerstrom-Nog, & Field-Fote, 2022[31]	Include	Include	~	SCI	Central Nervous System	RCT	16-Dose Wholebody Vibration	2 weeks	8	21.00	3	4	0.75

Articles in the final set of studies were categorized by the authors into treatment for 6 etiologies of neuropathic pain to enable sub-set analyses as follows (number of trials in brackets):

- CRPS: Complex regional pain syndrome type (1)
- DPN: Diabetic Peripheral Neuropathy (2)
- Other Disease: Sarcoid-associated small nerve fiber loss (1), Sickle Cell Disease pain (1)
- Post Infectious: Post-Herpetic Neuralgia (1)
- Central Nervous System: Brain or spinal cord injury (3)

- Surgical: Post-mastectomy pain (1), Post-cervical spine surgery pain (1), Post-discectomy radicular pain (1)

Table 1 lists the study characteristics for all included treatment arms and reported or derived statistics. The Standardized Mean Difference (Mean-Change/SD-of-Change) was calculated for any trial that that reported Mean-Change and SD-of-Change. Any adjustments necessary to estimate missing values or to correct NPSI scaling are reported in the Imputation Note column in Table 1 and were as follows:

- Rocha et al., 2014 [19]: The baseline SD was calculated using the reported Standard Error of the Mean (SEM) and the sample size (N).
- Rehm, Binder, & Baron, 2010 [24]: The NPSI total score was multiplied by 10 to bring it from 0-10 to a 0-100 score range.
- Raksakietisak et al., 2022 [25]: Reported baseline medians and quartiles were converted in to the baseline SD using the method presented in Wan et al., (2014) [26]
- Juhl, Karlsso, & Damsgaard 2016 [27]: The active arm reported a p value of < 0.001 for the improvement of the active arm over baseline. We estimated this to be a value $p = 0.00099$ and used the cumulative inverse distribution function to derive the T value for the test of mean change > 0. From the T value the SEM of change could be estimated by dividing the mean change by the T value. Finally, the SD of change was calculated by multiplying the SEM of change by the square root of the N.

There was a heterogeneous set of treatments and treatment durations in the sample of selected study arms. The interventions included pharmacological, nerve block, alternative,

220 neuromodulatory, and reconstructive treatments (see Table 1, Intervention column). Treatment
221 durations ranged from 1-hour single treatments to multiple dose regimens of up to 12 months.
222 The selected interventions were all from successful trials, where at least one of the treatment
223 arms was statistically different from control, thus the measures of change and variability reflect
224 those of a successful treatment. The inclusion of diverse interventions and treatments lengths into
225 the analyses limits the ability of to produce an aggregated MCID for any single treatment type.
226 The interpretation of the resulting MCID across this sample can be interpreted as the MCID for
227 successful treatments for the NPSI total across a diverse range of NP etiologies.
228
229 *Analyses:*
230 2 separate methods were employed to calculate the MCID for the NSPI. The first approach
231 replicates the method used by Watt et al. (2021), and first described by Furukawa et al., (2006),
232 to calculate distributionally based MCIDs for the clinical rating scale MMSE and ADAS-Cog
233 [32,33].
234
235 The first method calculates a pooled SD across the selected study arms by weighing each arms
236 variance by the arms sample size (N) (see Equation 1) such that arms with greater numbers of
237 participants are weighted more heavily. The pooled SD formula is typically applied to combine
238 the SD from 2 parallel arms in a Randomized Controlled Trial (RTC), however, it can be
239 extended to incorporate any number of treatment arms.
240
241 A pooled standard deviation was calculated across either all treatment arms or a categorical
242 subset using the following formula (Equation 1):

$$SD_{pooled} = \sqrt{\frac{\sum (n_i - 1) SD_i^2}{\sum (n_{i-1})}}$$

Where n_i is the number of participants and SD_i is the standard deviation from each treatment arm. Once the SD_{pooled} was calculated, the MCID was calculated as half of the SD_{pooled} Value (SD_{pooled} * 0.5). This analysis method was used to calculate MCIDs based on both the paired SD as well as the Baseline SD values.

For the analyses based on Equation 1, the SD of change is the most appropriate statistic to base a MCID upon as it is directly associated with the distribution of change scores resulting from the intervention. However, there is a limited amount of published data that reports the SD of change. Clinical trials almost always report baseline SD. While this source of variance does not capture any aspect of change resulting from the intervention, baseline SD captures variance inherent in the PRO, and has been shown to be highly predictive of the SD of change, and is an appropriate approximation for the calculation of an MCID [13,33,34].

The second approach employed random effect meta-analysis model to calculate the pooled effect size, mean, and SD [35]. Meta-analyses summary statistics, such as the pooled effect size or pooled mean change, are weighed by the variance of each study arm such that arms with lower variance are weighed more heavily.

Details on the random effect model are as follows:

- Hedges G effect size was calculated for each trial arm, as well as for the final pooled effect size.

- τ^2 was calculated across arms included in each analysis and used to compute study weights (not reported,).
- Pooled Effect Size and Pooled Mean Change were calculated by dividing sum of the individual arms statistics (mean change or SD of change) multiplied by the arm's weight divided by the sum of weights. See Formula 2 below:

$$M^* = \frac{\sum_{i=1}^{k} W_i^* Y_i}{\sum_{i=1}^{k} W_i^*}$$

Where M^* is the Pooled Statistic (SD-Pooled or Mean-Change-Pooled), k is the number of treatment arms, i denoted a specific treatment arm, W_i^* is the weighted random effect model variance for the arm (i), and Y_i is the statistic being pooled (SD-of-Change or Mean-Change) within each arm (i).

- The Pooled SD was derived by dividing the Pooled Mean Change by the Pooled Effect Size. The formula for SMD is Mean-Change / SD-of-Change, by rearranging this formula we can directly derive the Pooled SD.
- The MCID was calculated as half the Pooled SD (Pooled SD * 0.5)

The meta-analysis model was run for all trials that reported a mean change and SD of change, as well as for each neuropathy category.

The quality assessment indicates an overall low risk of bias in 75% of the 12 articles included in this. These findings are highlighted in Figures 2 and 3.

287 *Figure 2: Summary of quality assessment analysis*

288

289 *Figure 3: Overview of quality assessment analysis for 12 articles included in this meta-analysis*

290

291 **Results:**

292

293 *Pooled SD Method – SD of Change:*

294 The results for the SD of Change analyses are presented in Table 2. The results show that the
295 aggregated MCID across all arms that reported SD of change is 7.95 points on the NPSI total.
296 The range of MCIDs reported within each category were 7.24 to 9.

297

298 *Table 2: Results of the Pooled-SD-Method – SD-of-Change*

Category	# of Arms	N	Pooled SD	MCID
Total	11	384	15.91	7.95
Central Nervous System	4	181	14.48	7.24
Other Disease	3	46	14.94	7.47
Post Infectious	2	98	18	9
Surgical	2	59	17.04	8.52

299

300 *Pooled SD Method – Baseline SD*:

301 The results for the Baseline SD analyses are presented in Table 3. The results show that the
302 aggregated MCID across all arms that reported SD of change is 7.73 points on the NPSI total.
303 The range of MCIDs reported within each category were 3.65 to 9.14.

Table 3: Results of the Pooled-SD-Method – Baseline-SD

Category	**# of Arms**	**N**	**Pooled SD**	**MCID**
All Categories	15	303	15.45	7.72
CRPS	2	36	10.38	5.19
Central Nervous System	3	31	17.1	8.55
DPN	2	48	17.18	8.59
Other Disease	4	57	18.29	9.14
Post Infectious	2	98	15.8	7.9
Surgical	2	33	7.3	3.65

Random Effect Meta-Analysis:

The results for the random effect Meta-analysis are presented in Table 4. The results show that the aggregated MCID across all arms indicates that the MCID is 6.85 points on the NPSI total. The range of MCIDs reported within each category were 4.48 to 9.1.

Table 4: Results of the random effect meta-analysis

Category	# of Arms	N	Pooled Mean Change	Pooled SD of Change	Pooled Effect Size	MCID
All Categories	11	384	12.94	13.69	0.94	6.85
Other Disease	3	46	12	15.62	0.77	7.81
Post Infectious	2	98	15.03	18.19	0.83	9.1
Surgical	2	59	15.57	12.31	1.27	6.15
Central Nervous System	4	181	9.9	8.95	1.11	4.48

Discussion:

This meta-analysis has calculated three estimates of the MCID for the NPSI total score across a range of NP treatments and etiologies. MCID values are critical in clinical research as they provide a threshold to interpret whether observed improvements in symptom scales, such as the NPSI, reflect clinically meaningful changes for patients. These values aid clinicians and researchers in evaluating the practical impact of interventions and designing future trials.

The three methods examined in this meta-analysis produced similar estimates of the MCID. The estimates were 7.95 for the pooled SD change score method, 7.73 for the pooled SD baseline score method, and 6.85 for the random effect method. By using 3 separate methods, a conservative estimate of MCID can be determined by taking the highest MCID value of the 3

methods, which in this case is 7.95. The difference between the largest and smallest MCID is 1.1 points suggesting that these estimates were highly similar across methods suggesting that these results are approaching the true value. The pooled SD change score and random effects methods, based on change scores and their variance, are directly related to the actual measured improvement resulting from an intervention. In contrast, the baseline SD method is disconnected from any measured improvements in a trial, however, captures the variance inherent in the NPSI. Based on this reasoning, the baseline SD method is inherently more limited for producing an accurate MCID. However, applying the baseline SD method enabled the inclusion of more data and improved the robustness of MCID estimates across categories.

Examination of the sub-analyses of etiologies produces a different pattern of MCIDs depending on the method used. Table 5 summarizes the MCIDs found across the three methods and shows the average MCID by etiology.

Table 5: Aggregated and Mean MCID values across the 3 methods examined.

Etiology	**Change Score MCID**	**Baseline MCID**	**Meta-Analytic MCID**	**Mean MCID**
Central Nervous System	7.24	8.55	4.48	6.76
Other disease	7.47	9.14	7.81	8.14
Post-Infectious	9	7.9	9.1	8.67
Surgical	8.52	3.65	6.15	6.11
CRPS	~	5.19	~	5.19

DPN	~	8.59	~	8.59

Of the three methods, it can be observed in Table 5 above that the Baseline-SD method differed from both Change-Score-SD and Meta-Analytic methods, the latter 2 of which were similar. This can be explained by the Change-Score-SD and Meta-Analytic methods being based on change scores. Although the Baseline-SD varied from the other methods, it produced MCID estimates by etiology that were of similar values to the other 2 methods. This similarity supports the assumption that baseline SD can be used in place of change-score SD for the calculation of MCID. For this analysis, the baseline SD method was included to increase the number of study arms included in the analysis as baseline SD is typically reported more often in RTCs than within arm SD of change. CRPS and DPN did not have any published clinical trial that reported a change SD, and thus the baseline method was needed to estimate MCID for these etiologies. Table 5 computes the mean MCID across etiologies. Calculating the mean MCID per etiology produces an aggregated MCID that is likely closer to the true MCID.

The nature of pain may contribute to the variation in MCID between etiologies. Neuropathic pain is multifaceted, with a vast range of mechanisms and factors that contribute to patients' symptoms, therefore an improvement in certain pain characteristics may affect quality of life more than others. Changes in perceived intensity could affect the range, and thus the variance, of reported total pain scores in PROs which in turn would modulate an MCID based on distributional methods. For example, paroxysmal pain that feels like stabbing or electric shocks may be perceived as more painful than paresthesia pain that feels like pins and needles or tingling [36]. Paroxysmal NP is common in patients with post-surgical pain or CRPS, therefore a

370 modest improvement in pain is perceived as an impactful change by patients. In addition,
371 conditions that lead to central neuropathic pain or central sensitization of pain such as spinal cord
372 or brain injury, and CRPS, may also be felt more intensely than a small fiber or primarily
373 peripheral neuropathy from diabetes mellitus or sarcoidosis. This may be reflected by the
374 observation that the Central Nervous System, Surgical, and CRPS etiologies had the smallest
375 average MCIDs due to the possibility that they have an attenuated score range. Conversely,
376 patients with DPN are likely to experience paresthesias, meaning a more pronounced
377 improvement in pain may be required before is recognized as meaningful, suggesting greater
378 variability and that the MCID in these conditions may be larger than other etiologies. The NPSI
379 contains 5 subscales measuring specific symptom categories in NP such as burning pain,
380 pressing pain, paroxysmal pain, as well as paresthesia. Evaluating these NPSI subscales to
381 characterize pain for each NP etiology may confirm these explanations. For this meta-analysis
382 NPSI sub-scales were too infrequently reported to calculate individual MCIDs. Other factors
383 may also contribute to variation in MCID. Patients with chronic conditions are likely to
384 experience fluctuations in daily pain levels, which introduces a higher level of variance in the
385 sample, whereas post-surgical pain conditions are likely to improve more gradually over time,
386 however the timeframes of recovery vary.
387
388 The findings of this meta-analysis are pertinent for implementation of the NPSI in clinical care
389 and to facilitate the interpretation of clinical outcomes. Although the NPSI is a validated
390 assessment tool [8], a substantial number of screened studies used the NPSI to characterize pain.
391 While this suggests additional utility of the NPSI as a screening tool for classification, the NPSI
392 is underutilized as a primary outcome to quantify changes in neuropathic pain. The value of the

NPSI to discriminate distinct types of neuropathic pain for clinical evaluation is accepted, however the NPSI is also advantageous for monitoring neuropathic pain as it is validated and responsive to changes in each pain distinction [37].

Future research can improve the understanding of the MCID of the NPSI by publishing anchor-based estimates based on their trial data [7]. In addition, as more trials are published, distributionally and anchor-based estimates of MCID can be calculated that are specific to interventions and etiologies.

As the NPSI continues to be used as a metric of improvement in intervention trials for NP, understanding the MCID of this scale will become increasingly important. This meta-analysis produced distribution based MCID estimates from currently available published intervention trials. A limitation of this work is that since there are so few published trials using the NPSI each etiology only had a few trial arms to base a MCID upon. In order to estimate a general MCID for the NPSI it was necessary to aggregate across etiologies. However, treatment effects can be modulated within an etiology and future targeted MCID estimates based on large samples of data would allow more for precision in understanding the magnitude of clinical improvement within NP subtypes. While this analysis included a highly heterogenous set of interventions this is not a limitation as MCID values are not specific to an intervention, but rather to the scale itself. This analysis succeeds at producing an initial broad estimate of the MCID for the NPSI within NP. The results of this analysis are more relevant to the properties of the NPSI that indicate the clinically important magnitude of improvement on this PRO for NP in general and are less relevant for understanding the MCID of this scale for a specific NP etiology.

In conclusion, this meta-analysis has used distributional methods to produce estimates of the MCID for the NPSI total that are general across the examined etiologies and interventions. These estimates can be used to guide clinical trial design or to better understand the clinical importance of published NPSI total results.

Acknowledgements:

Dr. Jeffrey Bower is a paid employee of Sana Health, Inc. There are no conflicts of interest with any of the authors of this study. No sources of financial or other support to declare.

Additional material including analytic code, data extracted from individual studies, data for excluded studies, and quality analysis are available from the authors upon reasonable request. No review protocol is available. The review was not registered.

References:

1. Baron, R., Binder, A., & Wasner, G. (2010). Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. The Lancet Neurology, 9(8), 807-819
2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet, 390(10100), 1211-1259
3. Sadosky, A., McDermott, A. M., Brandenburg, N. A., & Strauss, M. (2013). A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Practice, 14(1), S56-S67. https://doi.org/10.1111/papr.12050
4. van Hecke, O., Austin, S. K., Khan, R. A., Smith, B. H., & Torrance, N. (2014). Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain, 155(4), 654-662
5. Treede, R.D., Rief, W., Barke, A., Aziz, Q., Bennett, M.I., Benoliel, R., Cohen, M., Evers, S., Finnerup, N.B., First, M.B. & Giamberardino, M.A., (2019). Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). pain, 160(1), 19-27
6. Scholz, J., Finnerup, N.B., Attal, N., Aziz, Q., Baron, R., Bennett, M.I., Benoliel, R., Cohen, M., Cruccu, G., Davis, K.D. & Evers, S., (2019). The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. PAIN, 160, 53–59.

7. Zhang, Y., Xu, L., Huang, Y. (2024). Update in the Treatment of Neuropathic Pain. In: Ma, C., Huang, Y. (eds) Translational Research in Pain and Itch. Springer, Singapore. https://doi.org/10.1007/978-981-99-8921-8_12
8. Attal, N., Bouhassira, D., & Baron, R. (2018). Diagnosis and assessment of neuropathic pain through questionnaires. The Lancet Neurology, 17(5), 456-466.
9. Haanpää, M. L., Attal, N., Backonja, M., Baron, R., Bennett, M., Bouhassira, D., ... & Treede, R. D. (2011). NeuPSIG guidelines on neuropathic pain assessment. PAIN®, 152(1), 14-27.
10. Bouhassira, D., Attal, N., Fermanian, J., Alchaar, H., Gautron, M., Masquelier, E., ... & Boureau, F. (2004). Development and validation of the neuropathic pain symptom inventory. Pain, 108(3), 248-257.
11. U.S. Food and Drug Administration. (2022, January 26). Principles for selecting, developing, modifying, and adapting patient-reported outcome instruments for use in medical device evaluation: Guidance for industry and Food and Drug Administration staff, and other stakeholders. https://www.fda.gov/media/141565/download
12. Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status: ascertaining the minimal clinically important difference. Controlled clinical trials, 10(4), 407-415.
13. Copay, A. G., Subach, B. R., Glassman, S. D., Polly Jr, D. W., & Schuler, T. C. (2007). Understanding the minimum clinically important difference: a review of concepts and methods. The Spine Journal, 7(5), 541-546.

14. Fritz, C. O., Morris, P. E., & Richler, J. J. (2012). Effect size estimates: Current use, calculations, and interpretation. Journal of Experimental Psychology: General, 141(1), 2-18. https://doi.org/10.1037/a0024338

15. McLeod, L. D., Coon, C. D., Martin, S. A., Fehnel, S. E., & Hays, R. D. (2011). Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert review of pharmacoeconomics & outcomes research, 11(2), 163-169.

16. Howard, R., Phillips, P., Johnson, T., O'Brien, J., Sheehan, B., Lindesay, J., Bentham, P., Burns, A., Ballard, C., Holmes, C. & McKeith, I., (2011). Determining the minimum clinically important differences for outcomes in the DOMINO trial. International journal of geriatric psychiatry, 26(8), 812-817.

17. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life. The remarkable universality of half a standard deviation. Med Care 2003;41:582–92

18. Higgins, J. P. T., Altman, D. G., & Sterne, J. A. C. (Eds.). (2011). Chapter 8: Assessing risk of bias in included studies. In J. P. T. Higgins & S. Green (Eds.), Cochrane handbook for systematic reviews of interventions (Version 5.1.0). The Cochrane Collaboration. Available from https://handbook-5-1.cochrane.org

19. de Oliveira Rocha, R., Teixeira, M.J., Yeng, L.T., Cantara, M.G., Faria, V.G., Liggieri, V., Loduca, A., Müller, B.M., Souza, A.C. & de Andrade, D.C., (2014). Thoracic sympathetic block for the treatment of complex regional pain syndrome type I: a double-blind randomized controlled study. PAIN®, 155(11), 2274-2281.

20. Hoerder, S., Habermann, I.V., Hahn, K., Meyer-Hamme, G., Ortiz, M., Grabowska, W., Roll, S., Willich, S.N., Schroeder, S., Brinkhaus, B. & Dietzel, J. (2023). Acupuncture in

495 diabetic peripheral neuropathy-neurological outcomes of the randomized acupuncture in
496 diabetic peripheral neuropathy trial. World journal of diabetes, 14(12), 1813.
497 21. Todorovic, M.S., Frey, K., Swarm, R.A., Bottros, M., Rao, L., Tallchief, D., Kraus, K.,
498 Meacham, K., Bakos, K., Zang, X. & Lee, J.B., (2022). Prediction of individual analgesic
499 response to intravenous lidocaine in painful diabetic peripheral neuropathy: a
500 randomized, placebo-controlled, crossover trial. The Clinical journal of pain, 38(2), 65-
501 76.
502 22. Schlaeger, J. M., Molokie, R. E., Yao, Y., Suarez, M. L., Golembiewski, J., Wilkie, D. J.,
503 & Votta-Velis, G. (2017). Management of sickle cell pain using pregabalin: a pilot study.
504 Pain Management Nursing, 18(6), 391-400.
505 23. Culver, D.A., Dahan, A., Bajorunas, D., Jeziorska, M., van Velzen, M., Aarts, L.P.,
506 Tavee, J., Tannemaat, M.R., Dunne, A.N., Kirk, R.I. & Petropoulos, I.N., (2017).
507 Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-
508 associated small nerve fiber loss and neuropathic pain. Investigative ophthalmology &
509 visual science, 58(6), BIO52-BIO60.
510 24. Rehm, S., Binder, A., & Baron, R. (2010). Post-herpetic neuralgia: 5% lidocaine
511 medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical
512 effectiveness study. Current medical research and opinion, 26(7), 1607-1619.
513 25. Raksakietisak, M., Rushatamukayanunt, P., Wilaiwan, K., Homprasert, C., Nitising, A.,
514 Sawasdiwipachai, P., & Pantubtim, C. (2022). Postoperative analgesia of intraoperative
515 nefopam in patients undergoing anterior cervical spine surgery: A prospective
516 randomized controlled trial. Medicine, 101(43), e31296.

517 26. Wan, X., Wang, W., Liu, J., & Tong, T. (2014). Estimating the sample mean and
518 standard deviation from the sample size, median, range and/or interquartile range. BMC
519 Medical Research Methodology, 14(1), 135. https://doi.org/10.1186/1471-2288-14-135
520 27. Juhl, A. A., Karlsson, P., & Damsgaard, T. E. (2016). Fat grafting for alleviating
521 persistent pain after breast cancer treatment: a randomized controlled trial. Journal of
522 Plastic, Reconstructive & Aesthetic Surgery, 69(9), 1192-1202.
523 28. Martinez, V., Szekely, B., Lemarié, J., Martin, F., Gentili, M., Ammar, S.B., Lepeintre,
524 J.F., de Loubresse, C.G., Chauvin, M., Bouhassira, D. & Fletcher, D., (2013). The
525 efficacy of a glial inhibitor, minocycline, for preventing persistent pain after lumbar
526 discectomy: a randomized, double-blind, controlled study. PAIN®, 154(8), 1197-1203.
527 29. Ushida, T., Katayama, Y., Hiasa, Y., Nishihara, M., Tajima, F., Katoh, S., Tanaka, H.,
528 Maeda, T., Furusawa, K., Richardson, M. & Kakehi, Y., (2023). Mirogabalin for central
529 neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled,
530 phase 3 study in Asia. Neurology, 100(11), e1193-e1206.
531 30. Kim, J. K., Park, H. S., Bae, J. S., Jeong, Y. S., Jung, K. J., & Lim, J. Y. (2020). Effects
532 of multi-session intermittent theta burst stimulation on central neuropathic pain: a
533 randomized controlled trial. NeuroRehabilitation, 46(1), 127-134.
534 31. Wong, M. L., Widerstrom-Noga, E., & Field-Fote, E. C. (2022). Effects of whole-body
535 vibration on neuropathic pain and the relationship between pain and spasticity in persons
536 with spinal cord injury. Spinal cord, 60(11), 963-970.
537 32. Watt, J. A., Veroniki, A. A., Tricco, A. C., & Straus, S. E. (2021). Using a distribution-
538 based approach and systematic review methods to derive minimum clinically important
539 differences. BMC Medical Research Methodology, 21, 1-7.

33. Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006). Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of clinical epidemiology, 59(1), 7-10.

34. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life. The remarkable universality of half a standard deviation. Med Care 2003;41:582–92

35. Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2021). Introduction to meta-analysis (2nd ed.). John Wiley & Sons.

36. Backonja, M.M. & Stacey B. (2004). Neuropathic pain symptoms relative to overall pain rating. J Pain, 5(9), 491-497.

37. Lucchetta, M., Pazzaglia, C., Padua, L., & Briani, C. (2011). Exploring neuropathic symptoms in a large cohort of Italian patients with different peripheral nervous system diseases. *Neurological Sciences*, *32*(3), 423–426.


Articles identified in literature search n= 323
Duplicates excluded n= 8
Articles screened by title and abstract n= 315
Articles excluded n= 241
Full-text articles assessed for eligibility n= 74
Articles excluded n= 54
Articles assessed for required statistics n= 20
Articles excluded n= 8
Articles included in meta-analysis n= 12

Figure 1


Bias arising from the randomization process
Bias due to deviations from intended interventions
Bias due to missing outcome data
Bias in measurement of the outcome
Bias in selection of the reported result
Overall risk of bias
0%
25%
50%
75%
100%
Low risk of bias
Some concerns
High risk of bias

Figure 2


Risk of bias domains
D1
D2
D3
D4
D5
Overall
Study
Ushida 2023
Rehm 2010
Culver 2017
Martinez 2013
Wong 2022
de Oliveira Rocha 2014
Schlaeger 2017
Hoerder 2023
Kim 2020
Todorovic 2022
Raksakietisak 2022
Juhl 2016
Domains:
D1: Bias due to randomisation.
D2: Bias due to deviations from intended intervention.
D3: Bias due to missing data.
D4: Bias due to outcome measurement.
D5: Bias due to selection of reported result.
Judgement
High
Some concerns
Low

Figure 3